Mutational analysis of circulating tumor cells from colorectal cancer patients and correlation with primary tumor tissue

PLoS ONE

Volumn 10, Issue 4, 2015, Pages

  Lyberopoulou, Anna ^a   Aravantinos, Gerasimos ^b   Efstathopoulos, Efstathios P ^a   Nikiteas, Nikolaos ^a   Bouziotis, Penelope ^c   Isaakidou, Athina ^b   Papalois, Apostolos ^d   Marinos, Evangelos ^a   Gazouli, Maria ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b Oncological Hospital Agioi Anargiroi   (Greece)

^c INSTITUTE OF NANOSCIENCE AND NANOTECHNOLOGY   (Greece)

^d Experimental Research Center ELPEN Pharmaceutical Co   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CD133 ANTIGEN; DNA; K RAS PROTEIN; PLASTIN3; QUANTUM DOT; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ALLELE; ARTICLE; BLOOD SAMPLING; CANCER PATIENT; CD133 GENE; CELL ISOLATION; CELL SUBPOPULATION; CELL SUSPENSION; CIRCULATING TUMOR CELL; COLORECTAL CANCER; CORRELATION ANALYSIS; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; NON INVASIVE MEASUREMENT; ONCOGENE; ONCOGENE BRAF; ONCOGENE K RAS; PERSONALIZED MEDICINE; PLASTIN3 GENE; POLYMERASE CHAIN REACTION; PRIMARY TUMOR; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SEQUENCE ANALYSIS; TUMOR BIOPSY; VERY ELDERLY; CANCER STEM CELL; COLORECTAL TUMOR; DNA MUTATIONAL ANALYSIS; EPITHELIAL MESENCHYMAL TRANSITION; EPITHELIUM CELL; FEASIBILITY STUDY; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; TUMOR EMBOLISM;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; COLORECTAL NEOPLASMS; DNA MUTATIONAL ANALYSIS; EPITHELIAL CELLS; EPITHELIAL-MESENCHYMAL TRANSITION; FEASIBILITY STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASTIC CELLS, CIRCULATING; NEOPLASTIC STEM CELLS;

EID: 84930616776     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0123902     Document Type: Article

References (52)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D, et al. Global cancer statistics. CA Cancer J Clin. 2011; 61: 69-90. doi: 10.3322/caac.20107 PMID: 21296855
2. Pawlik TM, Choti MA. Surgical therapy for colorectal metastases to the liver. J Gastrointest Surg. 2007; 11: 1057-77. PMID: 17530336
3. Alunni-Fabbroni M, Sandri MT. Circulating tumor cells in clinical practice: Methods of detection and possible characterization. Methods. 2010; 50: 289-297. doi: 10.1016/j.ymeth.2010.01.027 PMID: 20116432
4. Xenidis N, Perraki M, Kafousi M, Apostolaki S, Bolonaki I, Stathopoulou A, et al. Predictive and prognostic value of peripheral blood cytokeratin-19 mRNA-positive cells detected by real-time polymerase chain reaction in node-negative breast cancer patients. 2006; J Clin Oncol. 24: 3756-62. PMID: 16769987
5. Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis. Science. 2011; 331: 1559-64. doi: 10.1126/science.1203543 PMID: 21436443
6. Theodoropoulos PA, Polioudaki H, Agelaki S, Kallergi G, Saridaki Z, Mavroudis D, et al. Circulating tumor cells with a putative stem cell phenotype in peripheral blood of patients with breast cancer. Cancer Lett. 2010; 288: 99-106. doi: 10.1016/j.canlet.2009.06.027 PMID: 19619935
7. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002; 2: 442-54. PMID: 12189386
8. Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009; 360: 1408-17. doi: 10.1056/NEJMoa0805019 PMID: 19339720
9. Ciombor KK, Berlin J. Targeting metastatic colorectal cancer - present and emerging treatment options. Pharmgenomics Pers Med. 2014; 7: 137-44. doi: 10.2147/PGPM.S47582 PMID: 25045279
10. Jonker DJ, O'Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med. 2007; 357: 2040-8. PMID: 18003960
11. European Medicine Agency. Committee for Medicinal Products for human use post-authorization summary of positive opinion for Erbitux. Available at: http://emea.europa.eu/pdfs/human/opinion/Erbitux-28040208en.pdf
12. Allegra CJ, Jessup JM, Somerfield MR, Hamilton SR, Hammond EH, Hayes DF, et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol. 2009; 27: 2091-6. doi: 10.1200/JCO.2009.21.9170 PMID: 19188670
13. De Roock W, De Vriendt V, Normanno N, Ciardiello F, Tejpar S. KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. Lancet Oncol. 2011; 12: 594-603. doi: 10.1016/S1470-2045(10)70209-6 PMID: 21163703
14. Baldus SE, Schaefer KL, Engers R, Hartleb D, Stoecklein NH, Gabbert HE. Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. Clin Cancer Res. 2010; 16: 790-9. doi: 10.1158/1078-0432.CCR-09-2446 PMID: 20103678
15. Barault L, Veyrie N, Jooste V, Lecorre D, Chapusot C, Ferraz JM, et al. Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers. Int J Cancer. 2008; 122: 2255-9. doi: 10.1002/ijc.23388 PMID: 18224685
16. Mostert B, Jiang Y, Sieuwerts AM, Wang H, Bolt-de Vries J, Biermann K, et al. KRAS and BRAF mutation status in circulating colorectal tumor cells and their correlation with primary and metastatic tumor tissue. Int J Cancer. 2013; 133: 130-41. doi: 10.1002/ijc.27987 PMID: 23233388
17. Kalikaki A, Politaki H, Souglakos J, Apostolaki S, Papadimitraki E, Georgoulia N, et al. KRAS Genotypic Changes of Circulating Tumor Cells during Treatment of Patients with Metastatic Colorectal Cancer. PLoS One. 2014; 9:e104902. doi: 10.1371/journal.pone.0104902 PMID: 25137394
18. Sastre J, Maestro ML, Gómez-España A, Rivera F, Valladares M, Massuti B, et al. Circulating tumor cell count is a prognostic factor in metastatic colorectal cancer patients receiving first-line chemotherapy plus bevacizumab: a Spanish Cooperative Group for the Treatment of Digestive Tumors study. Oncologist. 2012; 17: 947-55. doi: 10.1634/theoncologist.2012-0048 PMID: 22643538
19. Krebs MG, Sloane R, Priest L, Lancashire L, Hou JM, Greystoke A, et al. Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer. J Clin Oncol. 2011; 29: 1556-63. doi: 10.1200/JCO.2010.28.7045 PMID: 21422424
20. Hayes DF, Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Miller MC, et al. Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res. 2006; 12: 4218-24. PMID: 16857794
21. Gutiérrez C, Rodriguez J, Patiño-García A, García-Foncillas J, Salgado J. KRAS mutational status analysis of peripheral blood isolated circulating tumor cells in metastatic colorectal patients. Oncol Lett. 2013; 6: 1343-1345. PMID: 24179521
22. Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer. 2009; 9: 265-73. doi: 10.1038/nrc2620 PMID: 19262571
23. Frederick BA, Helfrich BA, Coldren CD, Zheng D, Chan D, Bunn PA, et al. Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non-small cell lung carcinoma. Mol Cancer Ther.2007; 6: 1683-91. PMID: 17541031
24. Andrea C, Fausto P, Francesca BK, Mary C, Mara G, Veronica L, et al. Which strategy after first-line therapy in advanced colorectal cancer? World J Gastroenterol. 2014; 20: 8921-8927. doi: 10.3748/wjg.v20.i27.8921 PMID: 25083064
25. Xia T, Jiang H, Li C, Tian M, Zhang H. Molecular imaging in tracking tumor stem-like cells. J Biomed Biotechnol. 2012; 2012: 420364. doi: 10.1155/2012/420364 PMID: 22570529
26. Meregalli M, Farini A, Belicchi M, Torrente Y. CD133(+) cells isolated from various sources and their role in future clinical perspectives. Expert Opin Biol Ther. 2010; 10: 1521-8. doi: 10.1517/14712598.2010.528386 PMID: 20932225
27. Pohl A, El-Khoueiry A, Yang D, Zhang W, Lurje G, Ning Y, et al. Pharmacogenetic profiling of CD133 is associated with response rate (RR) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC), treated with bevacizumab-based chemotherapy. Pharmacogenomics J. 2013; 13: 173-80. doi: 10.1038/tpj.2011.61 PMID: 22231565
28. Joosse SA, Pantel K. Biologic challenges in the detection of circulating tumor cells. Cancer Res. 2013; 73: 8-11. doi: 10.1158/0008-5472.CAN-12-3422 PMID: 23271724
29. Ning Y, Gerger A, Zhang W, Hanna DL, Yang D, Winder T, et al. Plastin polymorphisms predict gender- and stage-specific colon cancer recurrence after adjuvant chemotherapy. Mol Cancer Ther. 2014; 13(2):528-39. doi: 10.1158/1535-7163.MCT-13-0646 PMID: 24170770
30. Yokobori T, Iinuma H, Shimamura T, Imoto S, Sugimachi K, Ishii H, et al. Plastin3 is a novel marker for circulating tumor cells undergoing the epithelial-mesenchymal transition and is associated with colorectal cancer prognosis. Cancer Res. 2013; 73: 2059-69. doi: 10.1158/0008-5472.CAN-12-0326 PMID: 23378342
31. Kaiser J. Medicine. Cancer's circulation problem. Science. 2010; 327: 1072-4. doi: 10.1126/science.327.5969.1072 PMID: 20185704
32. Gazouli M, Lyberopoulou A, Pericleous P, Rizos S, Aravantinos G, Nikiteas N, et al. Development of a quantum-dot-labelled magnetic immunoassay method for circulating colorectal cancer cell detection. World J Gastroenterol. 2012; 18: 4419-26. doi: 10.3748/wjg.v18.i32.4419 PMID: 22969208
33. Mélin C, Perraud A, Akil H, Jauberteau MO, Cardot P, Mathonnet M, et al. Cancer stem cell sorting from colorectal cancer cell lines by sedimentation field flow fractionation. Anal Chem. 2012; 84: 1549-56. doi: 10.1021/ac202797z PMID: 22236375
34. Königsberg R, Obermayr E, Bises G, Pfeiler G, Gneist M, Wrba F, et al. Detection of EpCAM positive and negative circulating tumor cells in metastatic breast cancer patients. Acta Oncol. 2011; 50:700-10 doi: 10.3109/0284186X.2010.549151 PMID: 21261508
35. Clevers H. The cancer stem cell: premises, promises and challenges. Nat Med. 2011; 17:313-9. doi: 10.1038/nm.2304 PMID: 21386835
36. Satelli A, Brownlee Z, Mitra A, Meng QH, Li S. Circulating tumor cell enumeration with a combination of epithelial cell adhesion molecule- and cell-surface vimentin-based methods for monitoring breast cancer therapeutic response. Clin Chem. 2015; 61:259-66. doi: 10.1373/clinchem.2014.228122 PMID: 25336717
37. Bonnomet A, Brysse A, Tachsidis A, Waltham M, Thompson EW, Polette M, et al. Epithelial-to-mesenchymal transitions and circulating tumor cells. J Mammary Gland Biol Neoplasia. 2010; 15: 261-73. doi: 10.1007/s10911-010-9174-0 PMID: 20449641
38. Ren F, Sheng WQ, Du X. CD133: a cancer stem cells marker, is used in colorectal cancers. World J Gastroenterol. 2013; 19: 2603-11. doi: 10.3748/wjg.v19.i17.2603 PMID: 23674867
39. Goutas N, Vlachodimitropoulos D, Bouka M, Lazaris AC, Nasioulas G, Gazouli M. BRAF and K-RAS mutation in a Greek papillary and medullary thyroid carcinoma cohort. Anticancer Res. 2008; 28: 305-8. PMID: 18383861
40. Hatzaki A, Razi E, Anagnostopoulou K, Iliadis K, Kodaxis A, Papaioannou D, et al. Modified mutagenic PCR-RFLP method for K-ras codon 12 and 13 mutations detection in NSCLC patients. Mol Cell Probes. 2001; 15: 243-7. PMID: 11735295
41. Allard WJ, Matera J, Miller MC, Repollet M, Connelly MC, Rao C, et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res. 2004; 10: 6897-904. PMID: 15501967
42. Maheswaran S, Haber DA. Circulating tumor cells: a window into cancer biology and metastasis. Curr Opin Genet Dev. 2010; 20: 96-9. doi: 10.1016/j.gde.2009.12.002 PMID: 20071161
43. Devriese LA, Voest EE, Beijnen JH, Schellens JH. Circulating tumor cells as pharmacodynamic biomarker in early clinical oncological trials. Cancer Treat Rev. 2011; 37: 579-89. doi: 10.1016/j.ctrv.2011.04.006 PMID: 21592671
44. Pinard R, de Winter A, Sarkis GJ, Gerstein MB, Tartaro KR, Plant RN, et al. Assessment of whole genome amplification-induced bias through high-throughput, massively parallel whole genome sequencing. BMC Genomics. 2006; 7: 216. PMID: 16928277
45. Wicha MS, Hayes DF Circulating tumor cells: not all detected cells are bad and not all bad cells are detected. J Clin Oncol. 2011; 29: 1508-11. doi: 10.1200/JCO.2010.34.0026 PMID: 21422428
46. Baas JM, Krens LL, Guchelaar HJ, Morreau H, Gelderblom H. Concordance of predictive markers for EGFR inhibitors in primary tumors and metastases in colorectal cancer: a review. Oncologist. 2011; 16: 1239-49. doi: 10.1634/theoncologist.2011-0024 PMID: 21742964
47. Alamgeer M, Peacock CD, Matsui W, Ganju V, Watkins DN. Cancer stem cells in lung cancer: Evidence and controversies. Respirology. 2013; 18: 757-64. doi: 10.1111/resp.12094 PMID: 23586700
48. Tanase CP, Neagu AI, Necula LG, Mambet C, Enciu AM, Calenic B, et al. Cancer stem cells: Involvement in pancreatic cancer pathogenesis and perspectives on cancer therapeutics. World J Gastroenterol. 2014; 20: 10790-10801. doi: 10.3748/wjg.v20.i31.10790 PMID: 25152582
49. Sinha N, Mukhopadhyay S, Das DN, Panda PK, Bhutia SK. Relevance of cancer initiating/stem cells in carcinogenesis and therapy resistance in oral cancer. Oral Oncol. 2013; 49: 854-62. doi: 10.1016/j.oraloncology.2013.06.010 PMID: 23876628
50. Shah MM, Landen CN. Ovarian cancer stem cells: are they real and why are they important? 2014; Gynecol Oncol. 132: 483-9. doi: 10.1016/j.ygyno.2013.12.001 PMID: 24321398
51. Sugimachi K, Yokobori T, Iinuma H, Ueda M, Ueo H, Shinden Y, et al. Aberrant Expression of Plastin-3 Via Copy Number Gain Induces the Epithelial-Mesenchymal Transition in Circulating Colorectal Cancer Cells.Ann Surg Oncol. 2013; [Epub ahead of print].
52. Christiansen JJ, Rajasekaran AK. Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis. Cancer Res. 2006; 66: 8319-26. PMID: 16951136